FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) has approved LEQEMBI IQLIK® (lecanemab-irmb) as a subcutaneous injection for the initiation dose in treating early Alzheimer's disease. This approval marks a significant development as it is described as a first-of-its-kind anti-amyloid treatment globally, offering at-home dosing for both initiation and maintenance.